CONTENTS

November 2009

Scientists have a strong incentive to make bold predictions—namely, to obtain funding, influence, and high-profile publications. But, as STUART BLACKMAN reports, while few will be disappointed when worst-case forecasts fail to materialize, unfulfilled predictions—of which we're seeing more and more—can be a blow for patients, policymakers, and for the reputation of science itself.

Related Articles

Authors of Our Own Misfortune

The Future of Public Engagement

The Scientist as Politician

The idea that the immune system could kill cancer cells has always been hotly debated. MARK J. SMYTH and his colleagues jumped into the mire and spent their careers investigating the death-inducing pathways that lymphocytes might use to suppress tumors. What they have found in mice suggests it might one day be possible to use the immune system to keep cancer in check.

Related Articles

When Cancer is Just the Beginning

Where Next for Cancer Immunotherapy?

Why Erbitux was Making People Sick

How does your institution rank? Check out this year's charts, and VICTORIA STERN's analysis of the results.

Related Articles

Small Powerhouse

Elevating Youth

Community Effort

A Promise for Young Talent

Top 40 US Academic Institutions

Top 15 US Academic Institutions

Top 10 International Academic Institutions

Respondent Demographics

Survey Methodology

CONTRIBUTORS

MAIL

EDITORIAL

Authors of Our Own Misfortune
Don't make promises you can't keep—please.
RICHARD GALLAGHER

COLUMN

Give Young Scientists a Break
I don't know if I could have even started my career in today's funding environment.
STEVEN WILEY

OPINION

NIH Continues to Support the Best Science Through R01s
A response to accusations that the agency is biased against senior scientists.
WALTER SCHAFFER AND SALLY ROCKEY

NOTEBOOK

Wounded cells
Six degrees of science
Drive-thru lab
In the muck
Tale of two tigers

FOUNDATIONS

First Primate Brain Map, circa 1917
JEF AKST

PROFILE

Calm in the STORm
Michael Hall has always gone his own way—a path that has opened up the field of growth regulation.
KAREN HOPKIN

SCIENTIST TO WATCH

Sheng Ding
As Cell Fate Would Have It
ELIE DOLGIN

BIO BUSINESS

Team of Rivals
Enlight Biosciences has a business model that's compelling enough to coax pharmaceutical companies to do something they rarely do—work together.
EDYTA ZIELINSKA

THE LITERATURE

A Theory Blossoms
Researchers unfold a key step in the process that tells plants to flower, findings that could one day benefit agriculture.
BOB GRANT

Hot paper in Molecular Biology: Can it be?
JEF AKST

Hot paper in Cell Biology: Hold the centrosomes
BOB GRANT

Hot paper in Genetics: Gene hunters
VICTORIA STERN

LAB TOOLS

Tailor-Made Mass Spec
Mass spec tinkerers describe their custom fixes for commercial hardware limitations.
JEFFREY M. PERKEL

CAREERS

Right your Writing
How to sharpen your writing and make your manuscripts more engaging.
BOB GRANT